文献速递肝病消化道肿瘤与早癌

酒精相关肝病与代谢功能障碍相关脂肪性肝病相继成为美国原发性肝癌增长最快的病因

Alcohol-Related Liver Disease, Followed by Metabolic Dysfunction-Associated Steatotic Liver Disease, Emerges as the Fastest-Growing Aetiologies for Primary Liver Cancer in the United States.
PubMed 文献 · Aliment Pharmacol Ther · 2025-01-05

该研究基于全球疾病负担研究2021数据,按性别、州和病因分析美国原发性肝癌负担,并用Joinpoint回归模型计算变化趋势。结果显示2000至2021年原发性肝癌发病率增加141%、死亡增加136%,年龄标化发病率和死亡率上升主要由酒精相关肝病和代谢功能障碍相关脂肪性肝病驱动。

要点

  • 2000至2021年美国原发性肝癌发病率增加141%、死亡增加136%。
  • 酒精相关肝病年龄标化发病率APC为+2.40%,死亡率APC为+2.22%。
  • 代谢功能障碍相关脂肪性肝病年龄标化发病率APC为+2.32%,死亡率APC为+2.04%。

核心结论

  • 过去二十年美国原发性肝癌负担上升,主要由酒精相关肝病驱动,其次为代谢功能障碍相关脂肪性肝病。

研究设计与样本

  • 基于全球疾病负担研究2021数据,提取美国原发性肝癌患病、发病、死亡和伤残调整生命年数据,按性别、州和病因分层,并用Joinpoint回归模型计算变化。

主要发现

  • 美国原发性肝癌有47,970例病例、31,450例发病、24,770例死亡和576,920伤残调整生命年。
  • 患病(16,980)、发病(12,040)、死亡(9,840)和伤残调整生命年(213,410)最高者均由慢性丙型肝炎病毒感染所致。
  • 2000至2021年原发性肝癌发病率增加141%,死亡增加136%。
  • 每10万人口年龄标化发病率与死亡率上升,主要由酒精相关肝病(发病率APC +2.40%;死亡率APC +2.22%)和代谢功能障碍相关脂肪性肝病(发病率APC +2.32%;死亡率APC +2.04%)驱动。

临床怎么用

  • 作者认为这些发现为政策制定者准确评估原发性肝癌负担提供了依据,并强调需针对危险因素进行干预,尤其是酒精相关政策。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Primary liver cancer (PLC) is projected to be the third leading cause of cancer mortality in the United States in 2040. We examine the burden of PLC in the United States, stratified by sex, state and aetiological risk factors. METHODS: Data on PLC prevalence, incidence, death and disability-adjusted life years (DALYs) were extracted from the Global Burden of Disease Study 2021. Changes in these parameters were calculated using the Joinpoint regression model. RESULTS: There were 47,970 cases, 31,450 incident cases, 24,770 deaths and 576,920 DALYs from PLC in the United States. The highest prevalence (16,980), incidence (12,040), death (9840) and DALYs (213,410) from PLC were due to chronic hepatitis C virus infection. From 2000 to 2021, PLC incidences increased by 141%, and PLC deaths increased by 136%. Age-standardised incidence rates (ASIRs) and death rates (ASDRs) per 100,000 population for PLC increased, primarily driven by alcohol-related liver disease (ALD) (ASIR: annual percent change [APC]: +2.40%; ASDR: APC: +2.22%) and metabolic dysfunction-associated steatotic liver disease (MASLD) (ASIR: APC: +2.32%; ASDR: APC: +2.04%). CONCLUSION: The burden of PLC in the United States has risen in the past two decades, driven mainly by ALD and followed by MASLD. These findings offer policymakers an accurate assessment of the PLC burden and emphasise the need for targeted risk factor mitigation, especially regarding alcohol related policy.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Danpanichkul P, Duangsonk K, Kalligeros M, et al. Alcohol-Related Liver Disease, Followed by Metabolic Dysfunction-Associated Steatotic Liver Disease, Emerges as the Fastest-Growing Aetiologies for Primary Liver Cancer in the United States. Aliment Pharmacol Ther. 2025. PMID: 39757456. doi:10.1111/apt.18473

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。